ELQ 300

ELQ-300 is an experimental antimalarial medication. It is an endochin-like quinolone and the first in a new class of antimalarials known as quinolone-3-diarylethers.

ELQ-300 acts as an inhibitor of the mitochondrial cytochrome bc₁ complex (complex III in the electron transport chain). In preclinical studies with mice, it was found to be highly active against Plasmodium falciparum and Plasmodium vivax at all life cycle stages that play a role in the transmission of malaria, and to have good oral bioavailability.